We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Mologic Expands US and UK Operations

Steve Fletcher, President of Mologic Inc. & Chief Commercial Officer, Mologic

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Mologic Expands US and UK Operations"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, services and products, announced it has completed the latest phase of the Company’s expansion plans. Significant to this has been the opening of a US subsidiary and key appointments made at both US and UK sites. The recent developments bolster Mologic’s presence in the US and support the expansion of UK-based manufacturing facilities.

Key appointments include Steve Fletcher as President of Mologic Inc. and Chief Commercial Officer, heading the Company’s US Headquarters located just outside of Boston, MA. Steve will be working to broaden Mologic’s presence in the US, building commercial operations for strategic partnering and contract research, and developing the Company’s internal product pipeline. Steve has over 25 years’ experience in leading marketing, product and business operations for global healthcare companies including 3M, Thermo Fisher and GC America.

Mologic’s Executive team has been further strengthened with the appointments of Tim Dwyer as Chief Technology Officer (CTO) and Dr. Joseph Fitchett as Chief Medical Officer (CMO) & Head of Global Health to support the expansion of its UK facilities.

Tim recently joined Mologic as CTO to lead technical and scientific functions, and drive internal product activities. He is a Chartered Biologist and a Fellow of the Royal Society of Biology with over 19 years of experience in the design and development of diagnostic devices on multiple immunoassay platform technologies. Tim’s appointment supports the expansion of Mologic’s UK facilities which includes the consolidation the Company’s Molecular Antibody Development and Recombinant Protein Expression business units into a single specialist facility and the doubling of device manufacturing capacity.

As CMO, Joe has responsibility for strengthening the Company’s ties with the clinical community and directing its Global Health programmes. In his previous role as a Program Officer at the Bill & Melinda Gates Foundation, Joseph advanced the foundation’s bilateral partnerships with EU donors, including the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control at the Institut Pasteur in Dakar. Joseph trained in clinical medicine at Imperial College London, Guy’s and St Thomas’ Hospital, and in immunology of infectious diseases at The London School of Hygiene & Tropical Medicine.

Supporting the latest phase in expansion, Mologic has made further appointments to its US team, including Stephen Crossland as VP of Sales and Business Development, and Andrew Wheeler as US R&D Manager. Stephen has over 10 years’ experience in the sales and commercialisation of medical technologies, and will be directing commercial efforts, and identifying strategic partners for Mologic’s key focus areas. Andrew is joining the team with over 18 years’ experience in rapid diagnostics development, and will be working with Stephen to support Mologic’s new and existing US customers by providing technical expertise and support in diagnostic development.

Steve Fletcher, President, Mologic Inc. and Chief Commercial Officer said: “The opening of our US headquarters is key to expanding Mologic’s presence in North America, not only in terms of supporting new and existing contract research customers, but also in developing clinical and industry partnerships to commercialise our product pipeline. The science and technology, and diagnostic development experience that exists in Mologic is world class, so it is key we build an experienced team in the US to tell the Mologic story. We are already seeing great opportunity, which I look forward to progressing.”

Mark Davis, Mologic Co-Founder and Chief Executive Officer, commented: “Following the series of successful fundraising rounds, we continue to invest in the Mologic expert team and facilities. Opening a US office and recent UK expansion is key to delivering our ambitious growth strategy and I look forward to working with Steve, Tim, Joe and the rest of the team, in further establishing Mologic as the leading developer of lateral flow and rapid diagnostic technologies.”